View Older Stories View More Recent Stories

Apr 24, 2024 04:42PM Nanometrics (NANO) Issues Business Update, Reports FY23 Results
Apr 24, 2024 04:40PM NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
Jan 11, 2024 04:32PM Voting Rights and Shares Capital of the Company
Oct 11, 2023 04:27PM Voting Rights and Shares Capital of the Company
Sep 19, 2023 04:15PM Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023
May 5, 2023 01:30AM NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company
Apr 25, 2023 05:19AM Nanobiotix (NBTX) Provides Business Update, Reports FY22 Results
Apr 24, 2023 07:33PM NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
Apr 17, 2023 04:15PM NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
Apr 11, 2023 04:15PM Voting Rights and Shares Capital of the Company
Mar 27, 2023 04:15PM Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
Mar 14, 2023 04:15PM Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
Feb 14, 2023 04:15PM Voting Rights and Shares Capital of the Company
Jan 11, 2023 04:15PM Voting Rights and Shares Capital of the Company
Dec 27, 2022 01:45AM NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
Dec 21, 2022 04:19PM Nanometrics, Inc. (NBTX) Terminates Liquidity Contract; Publishes End of Contract Statement
Dec 21, 2022 04:15PM NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
Dec 8, 2022 04:15PM Voting Rights and Shares Capital of the Company
Nov 15, 2022 04:15PM NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
Nov 14, 2022 04:16PM NANOBIOTIX (NBTX) Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
Nov 14, 2022 04:15PM NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
Nov 10, 2022 05:49AM NANOBIOTIX (NBTX) Reports Updated Phase 1 Anti-PD-1 Combination Data
Nov 10, 2022 02:00AM NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of C
Nov 9, 2022 04:15PM NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
Nov 8, 2022 04:15PM NANOBIOTIX Voting Rights and Shares Capital of the Company
Nov 2, 2022 04:15PM NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
Oct 31, 2022 04:15PM NANOBIOTIX to Present at the Jefferies London Healthcare Conference
Oct 27, 2022 04:15PM NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
Oct 18, 2022 04:15PM NANOBIOTIX (NBTX) Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
Oct 18, 2022 04:15PM NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
Oct 10, 2022 04:15PM Nanobiotix: Voting Rights and Shares Capital of the Company
Sep 28, 2022 04:15PM Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022
Sep 22, 2022 04:15PM Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022
Sep 21, 2022 04:15PM Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy
Sep 12, 2022 05:35AM Nanobiotix (NBTX) Enters Agreement to Restructure EUR 30.7M Loan
Sep 12, 2022 02:00AM Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024
Sep 8, 2022 04:15PM Nanobiotix: Voting Rights and Shares Capital of the Company
Sep 7, 2022 04:15PM NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer
Sep 6, 2022 04:15PM NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences
Aug 31, 2022 04:15PM Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022
Aug 9, 2022 04:15PM NANOBIOTIX: Voting Rights and Shares Capital of the Company
Jul 13, 2022 04:15PM Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont
Jul 8, 2022 04:15PM Nanobiotix: Voting Rights and Shares Capital of the Company
Jun 9, 2022 04:15PM NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Jun 5, 2022 09:00AM NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications
Jun 2, 2022 04:15PM NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022
May 18, 2022 09:12PM CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update
May 18, 2022 04:40PM NANOBIOTIX Provides First Quarter Operational and Financial Update
May 17, 2022 04:15PM NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
May 11, 2022 04:15PM NANOBIOTIX to Participate in Two Upcoming Investor Conferences
View More Recent Stories View Older Stories